Cumulative incidence estimates of CMV infection and disease: principal efficacy population
| CMV infection end point . | Oral acyclovir n = 361 . | Valacyclovir n = 366 . | ||
|---|---|---|---|---|
| Cumulative incidence estimates, % . | Incidence, % . | Cumulative incidence estimates, % . | Incidence, % . | |
| Blood, BAL, or disease | 44 | 40 | 33 | 28 |
| Disease or any positive culture | 53 | 50 | 40 | 34 |
| Blood | 41 | 39 | 29 | 26 |
| Urine | 34 | 28 | 20 | 14 |
| BAL | 3 | — | 2 | — |
| Definitive CMV disease | 4 | 3.6 | 4 | 2.5 |
| Presumed/definitive CMV disease | 6 | 5.5 | 5 | 3.5 |
| Presumed CMV disease | 1.9 | — | 1.0 | — |
| CMV infection end point . | Oral acyclovir n = 361 . | Valacyclovir n = 366 . | ||
|---|---|---|---|---|
| Cumulative incidence estimates, % . | Incidence, % . | Cumulative incidence estimates, % . | Incidence, % . | |
| Blood, BAL, or disease | 44 | 40 | 33 | 28 |
| Disease or any positive culture | 53 | 50 | 40 | 34 |
| Blood | 41 | 39 | 29 | 26 |
| Urine | 34 | 28 | 20 | 14 |
| BAL | 3 | — | 2 | — |
| Definitive CMV disease | 4 | 3.6 | 4 | 2.5 |
| Presumed/definitive CMV disease | 6 | 5.5 | 5 | 3.5 |
| Presumed CMV disease | 1.9 | — | 1.0 | — |